Firms to investigate RNAi for Huntington's disease

12/27/2010 | Wall Street Journal, The

Alnylam Pharmaceuticals and Medtronic have teamed up to develop a treatment for Huntington's disease using RNA interference, which can focus on a gene responsible for the production of disease-causing proteins. Medtronic will develop a catheter or a pump that can deliver Alnylam's short, interfering RNA drug directly to the correct area of the brain.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC